XJZY(SZ:002332)2024-08-28 01:28Financial Performance - In the first half of 2024, the company achieved operating revenue of 213,784.76 million yuan, a year-on-year increase of 0.93% [2] - Operating profit reached 40,935.84 million yuan, with a growth of 16% [2] - Total profit amounted to 40,712.32 million yuan, reflecting a 16% increase year-on-year [2] - Net profit attributable to shareholders was 33,972.24 million yuan, up by 12.56% [2] - The net profit after deducting non-recurring gains and losses was 33,147.99 million yuan, an increase of 11.78% [2] - Earnings per share were 0.34 yuan, a year-on-year growth of 9.68% [2] Revenue Structure - The main business revenue was 21.25 billion yuan, with a 1% year-on-year increase [3] - Revenue from formulation sales was 12.15 billion yuan, up by 10.6% [3] - Self-operated product sales contributed 11.63 billion yuan, a 9% increase [3] - Distribution sales from the pharmaceutical expansion department were 0.52 billion yuan [3] - Revenue from raw materials and intermediates was 9.1 billion yuan, down by 9% [3] - Self-operated raw material sales were 4.89 billion yuan, a decrease of 1.2% [3] - Sales from the Italian subsidiary were 2.97 billion yuan, down by 15% [3] Key Product Performance - Gynecological products generated 2.33 billion yuan, a decrease of 1% [3] - Anesthesia and muscle relaxant products saw sales of 0.63 billion yuan, an increase of 28% [3] - Respiratory products achieved sales of 3.93 billion yuan, up by 30% [3] - Dermatological products generated 1.2 billion yuan, reflecting a 26% increase [3] - General medicine products saw a decline of 6%, primarily due to the impact of centralized procurement [3] R&D and Innovation - R&D expenses for the first half of 2024 were 125 million yuan, with a growth rate of 33.8% compared to the previous year [4] - The company aims to maintain suitable investment levels in R&D to support ongoing development [5] Market Strategy and Challenges - The company is focusing on expanding its product portfolio and enhancing sales capabilities to counteract the effects of centralized procurement [4] - The raw material market remains competitive, with prices at a low level, necessitating strategic market expansion [6] - The company emphasizes the importance of product registration capabilities and quality improvement to enhance competitiveness in international markets [7]